We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Beckman Coulter Selects SAFC Supply Solutions as Licensing Partner
News

Beckman Coulter Selects SAFC Supply Solutions as Licensing Partner

Beckman Coulter Selects SAFC Supply Solutions as Licensing Partner
News

Beckman Coulter Selects SAFC Supply Solutions as Licensing Partner

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Beckman Coulter Selects SAFC Supply Solutions as Licensing Partner"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SAFC, a member of the Sigma-Aldrich Group has announced that its Supply Solutions business segment has received a license for Beckman Coulter's fast deprotection chemistry.

The agreement covers Beckman Coulter's acetyl-protected cytidine DNA- and 2'-O-methyl phosphoramidites for the synthesis of oligonucleotides. These chemistries collapse cleavage and deprotection timelines to mere minutes, while completely maintaining the integrity of synthesized DNA and RNA.

SAFC is the first company licensed to the full range of these phosphoramidites, which will be produced at their Proligo® Reagents ISO 9001-certified manufacturing facility in Hamburg, Germany.

The licensing agreement expands SAFC's oligo synthesis reagents offer in the sector. The agreement coincides with the U.S. TIDES® 2007 conference being held in Las Vegas, Nevada on May 20 - 23, 2007.

Dr. Andreas Wolter, SAFC's Proligo Reagents Managing Director, said, "Oligo therapeutics are now the focus of over 120 preclinical studies or clinical trials and the industry has seen investments of over $3.5 billion in the past four years. Our licensing agreement with Beckman Coulter provides customers with access to these key components in oligonucleotides synthesis.”

Mr. Wolter continued, “Use of fast deprotection technology, supported by proven high-quality and consistency of SAFC Proligo Reagents will benefit scientists across research, pharmaceutical and diagnostic applications. Given the growing momentum in oligo therapeutics, we are delighted to have this opportunity to team with Beckman Coulter."

"We are pleased to grant this technology license to SAFC," said Chris Neary, Vice President of Beckman Coulter's Discovery Products Business Center. "We are confident that SAFC will produce and deliver high-quality products to customers working in the field of genetics."

Advertisement